Johnson & Johnson has said the impending spin-off of its consumer health division won't stop it from "forging ahead" with M&A deals to expand its other businesses including pharma a
Johnson & Johnson's much-touted crop of bispecific antibodies for cancer generated its first commercial product in May, and the drugmaker has now filed for FDA approval of a second cand
This episode of the pharmaphorum podcast is the second in a limited series focused on patient engagement that’s being led by clinician, consultant and patient advocate, Mark Duman.
Johnson & Johnson's also-ran COVID-19 vaccine has been cleared in the EU as a booster shot, although its role in the US could be impacted by new data on rare blood clots.
Bayer's Nubeqa is making headway as a treatment for castration-resistant prostate cancer (CRPC), but could be on track to expand its eligible patient population thanks to new phase 3 data.<
Targeted cancer drug specialist Blueprint Medicines has agreed to pay $250 million upfront to acquire Lengo Therapeutics and its lead drug for lung cancer, a rival to already-approved thera